APP and Alzheimer disease: When the level of CTGF was reduced in APP/PS1 transgenic AD mice by tauroursodeoxycholic acid (TUDCA) supplemented, hippocampal and prefrontal amyloid deposition were decreased, and the spatial, recognition and contextual memory defects were also prevented10,12.